U Gluck1, U Martin, B Bosse, K Reimer, S Mueller. 1. ENT Unit, Division of Occupational Medicine, Suva Swiss National Accident Insurance Institute, Lucerne, Switzerland. glw@suva.ch
Abstract
PURPOSE OF STUDY: This phase I study assessed tolerability and local effect of a liposome dispersion with povidone-iodine (polyvinylpyrrolidone-iodine, PVP-I) as nasal spray. PROCEDURES: Three groups received liposomal dispersion with PVP-I (2.2, 4.4 and 0% as control) in single and repeated use (3 days, three times a day). A set of functional and cytological tests as well as safety assessments were performed. RESULTS: No safety-relevant finding or serious adverse events were reported, no evidence for cyto- nor genotoxicity obtained. No clinically relevant changes in mucosa appearance, nor in olfactory sense, nor in ciliary activity (sensitive indicator of local tolerance) occurred and no complaints about nasal airflow obstruction were observed. All liposomal formulations had a positive effect on the nasal mucosa, challenged by allergy in some volunteers. CONCLUSIONS AND MESSAGE: Application of liposomal PVP-I spray to the nasal mucosa does not result in any demonstrable limitation of the nasal function nor in detectable damage to the multilayer ciliated epithelium of the nose. Improvement of various parameters of nasal function under liposomal PVP-I suggest improved mucociliary clearance. Explanation could be humidification, improved surfactant (phospholipid) level and/or sufficient mucolytic activity of iodide due to local application of the constituents.
RCT Entities:
PURPOSE OF STUDY: This phase I study assessed tolerability and local effect of a liposome dispersion with povidone-iodine (polyvinylpyrrolidone-iodine, PVP-I) as nasal spray. PROCEDURES: Three groups received liposomal dispersion with PVP-I (2.2, 4.4 and 0% as control) in single and repeated use (3 days, three times a day). A set of functional and cytological tests as well as safety assessments were performed. RESULTS: No safety-relevant finding or serious adverse events were reported, no evidence for cyto- nor genotoxicity obtained. No clinically relevant changes in mucosa appearance, nor in olfactory sense, nor in ciliary activity (sensitive indicator of local tolerance) occurred and no complaints about nasal airflow obstruction were observed. All liposomal formulations had a positive effect on the nasal mucosa, challenged by allergy in some volunteers. CONCLUSIONS AND MESSAGE: Application of liposomal PVP-I spray to the nasal mucosa does not result in any demonstrable limitation of the nasal function nor in detectable damage to the multilayer ciliated epithelium of the nose. Improvement of various parameters of nasal function under liposomal PVP-I suggest improved mucociliary clearance. Explanation could be humidification, improved surfactant (phospholipid) level and/or sufficient mucolytic activity of iodide due to local application of the constituents.
Authors: Mostafa Kamal Arefin; Sultana Sahana Banu; A K M Nasir Uddin; S K Nurul Fattah Rumi; Mala Khan; Ahsanul Kaiser; Muhammad Shaharior Arafat; Joybaer Anam Chowdhury; Md Abdullah Saeed Khan; Mohammad Jahid Hasan Journal: Indian J Otolaryngol Head Neck Surg Date: 2022-05-06
Authors: Nicole-Ann Lim; Ooiean Teng; Chester Yan Hao Ng; Lena X Y Bao; Paul Anantharajah Tambyah; Amy M L Quek; Raymond C S Seet Journal: Ann Med Date: 2022-12 Impact factor: 5.348
Authors: Harman S Parhar; Kendall Tasche; Robert M Brody; Gregory S Weinstein; Bert W O'Malley; Rabie M Shanti; Jason G Newman Journal: Head Neck Date: 2020-04-25 Impact factor: 3.147